HC: The investment in Hangzhou Liangzhi Joint Technology Co., Ltd. is currently executing a relatively small order scale
HC announced that due to the closing price deviation exceeding 30% for three consecutive trading days, it constitutes abnormal volatility. The company will invest 30 million yuan in the first half of 2025 to hold a 30% equity stake in Hangzhou Liangzhi Joint Technology Co., Ltd., which focuses on the humanoid robot industry chain, mainly researching and producing products such as harmonic reducers. Currently, due to limitations in the mass production scale and R&D progress of downstream customers, the execution order scale is relatively small, and revenue is also low
According to the Zhitong Finance APP, HC (301008.SZ) announced that the cumulative closing price deviation of its stock has exceeded 30% over three consecutive trading days (September 16, 2025, September 17, 2025, and September 18, 2025). This situation falls under the category of abnormal stock trading fluctuations according to the relevant regulations of the Shenzhen Stock Exchange.
The company has noted the recent high market attention on humanoid robot-related concepts. In its "2025 Semi-Annual Report," the company disclosed its situation in related businesses. In the first half of 2025, the company invested 30 million yuan in Hangzhou Liangzhi Joint Technology Co., Ltd., holding a 30% stake in the company. This company focuses on the humanoid robot-related industry chain and is mainly engaged in the research, development, production, and sales of harmonic reducers, planetary reducers, and joint modules. Investors are reminded that, due to the production scale of downstream customers and the progress of research and testing, the current execution order scale is relatively small, and the revenue scale is also small
